新临床肥胖框架与传统BMI分类在中年英国成人中的比较
Rethinking obesity: comparison of the new clinical obesity framework with traditional BMI-based classifications in midlife UK adults
该研究在1970年英国出生队列中评估了新临床肥胖框架与传统BMI分类的差异,发现使用新框架分类的临床肥胖比例为17.7%,而BMI分类为肥胖的比例仅为32.4%,其中仅31.4%的BMI肥胖者符合临床肥胖标准。新框架能更准确地识别出高风险肥胖人群。
Introduction
Despite widespread use in clinical and research settings, body mass index (BMI) has been criticised as a tool for identifying obesity in the general population [1]. BMI fails to differentiate between fat and muscle mass, capture fat distribution, and ignores age, sex or ethnicity-related differences [1]. A recent Lancet-commissioned clinical framework sought to move beyond BMI and “establish objective criteria for disease diagnosis, aiding clinical decision-making and prioritisation of therapeutic interventions and public health strategies” [2]. The new definition incorporates three elements to distinguish between no obesity, pre-clinical obesity and clinical obesity: excess adiposity, functional limitations, and obesity-related organ dysfunction. Given the recency of the framework, there has been limited exploration of this framework in population representative cohort studies [3, 4]. As such, there is a need to explore and compare how the clinical obesity framework differs from previous standard BMI-based definitions. Therefore, the primary aim of this study was to estimate the prevalence of pre-clinical and clinical obesity in midlife, and explore discordance with the standard BMI-based definition. Secondary aims were to explore differences in demographic, behavioural, and health indicator characteristics across BMI and clinical obesity categories and to examine associated five-year mortality risks.
Methods
Participants were drawn from the age 46 follow-up of the 1970 British Cohort Study (BCS70), a nationally representative study of individuals born in England, Scotland, and Wales during one week in 1970 [5]. The age 46 wave (n = 8581) included questionnaires, interviews and biomedical assessments. We operationalized the new framework using measures of excess adiposity, functional limitations and obesity-related organ dysfunction that mapped on to Lancet commission framework [2]; see Table 1 for items and thresholds for each component and Supplementary Text 1 for full definitions and coding. Individuals were classified as having no obesity (no excess adiposity), pre-clinical (excess adiposity only), or clinical obesity (excess adiposity with functional limitations and/or organ dysfunction). The same individuals were re-categorised using standard WHO BMI cut-points [6]: underweight (<18.5 kg/m2), healthy (18.5–25.0 kg/m²), overweight (25.0–29.9 kg/m²), and obesity (≥30.0 kg/m²). The correlation between the clinical obesity and BMI definitions was assessed using Spearman’s rank correlation coefficient, with Fisher’s z-transformation used to compare correlations between sexes.
Characteristics of each clinical obesity and BMI category were described using means ± SD and frequencies/proportions across four demographic (sex, education, occupation, marital status), six health behaviours (smoking status, alcohol consumption, 24-h movement including daily time in total physical activity, moderate-vigorous physical activity, sedentary behaviour, sleep) and six health indicators (self-reported health, disability status, verbal memory task, blood pressure, malaise, wellbeing). See Supplementary Table 1 for detailed description of variable ascertainment [7,8,9,10,11,12,13,14]. One-way ANOVAs and chi-square tests were used to explore differences in characteristics by obesity/BMI category. Finally, logistic regressions were used to explore sex-adjusted risk ratios for obesity status and a binary five-year mortality outcome; models were not adjusted for covariates due to limited statistical power. Further information on participant response at age 51 and mortality data is described elsewhere [15, 16]. All analyses were conducted in RStudio 4.4.3; packages used include dplyr, ggplot2, scales, patchwork, janitor and tidyr.
Results
Among 8581 individuals who participated in the age 46 data collection wave, 6978 (81.3% of sample; 52% female) participants had complete data on both obesity definitions. Missing data was largely attributable to individuals missing the adiposity test data required to derive the clinical obesity status (see Supplementary Table 1 for %); these individuals (n = 1515; mean BMI 31.8 ± 8.0) had a higher BMI than the included sample (n = 6978; 27.1 ± 5.1). Of the included sample size, 29.8% had no obesity, 52.5% were classified as pre-clinical obesity and 17.7% met criteria for clinical obesity. Using BMI cut-points, 0.7% were considered underweight, 29.1% healthy weight, 37.8% overweight, and 32.4% as having obesity. Of those with BMI-defined obesity (≥30 kg/m²), only 31.4% were also classified as clinical obesity, with the majority (68.6%) falling into the pre-clinical category (Fig. 1). Though two thirds (65%) of those classified as BMI-overweight were also classified as pre-clinical obesity, 16.6% also met criteria for clinical obesity (indicating a group at elevated risk that would be missed by BMI alone) and 18% had no obesity (indicating a lower risk/morbidity group than BMI alone would suggest). Of note, 98% (49/50) of individuals with BMI < 18.5 kg/m2 were classified as having no obesity, with a single male meeting the criteria of clinical obesity. Patterns were consistent across sex, with slightly stronger correlation between definitions in females (Spearman ρ = 0.68 in females, 0.53 in males; Fisher’s z transformation = 9.69, p < 0.001).
Comparison of clinical obesity and BMI category classifications in the overall sample (n = 6978), females (n = 3635) and males (n = 3343).
Differences in demographic, health behaviours and health indicator characteristics by obesity status were similar across both clinical obesity and BMI category definitions. Those in the highest obesity category (e.g. clinical obesity, BMI 30+kg/m2) were more likely to be female, have lower educational attainment or work in a manual occupation. They were also more likely to be a non-drinker and engaged in less total and moderate-vigorous physical activity, more sedentary behaviour and less sleep. Those in the highest obesity definitions had poorer health across all health indicators: worse self-reported health, greater disability, poorer verbal memory, higher blood pressure, higher Malaise scores and lower wellbeing. Supplementary Tables 1, 2 provide full characteristics across the three clinical obesity and four BMI categories, respectively. There was no association between the clinical obesity definition and each of marital or smoking status, with trends for differences in BMI groups driven largely by the underweight category.
Of those with valid clinical obesity and BMI data at age 46, 27(0.4%) died by age 51 follow-up. Compared to those with no obesity (n = 3 deaths; 0.2%), those with pre-clinical obesity (n = 15 deaths; 0.5%) or clinical obesity (n = 9 deaths; 0.8%) had 2.82 (95% CI: 0.93, 12.2) and 5.17 (1.54, 23.3) greater odds of death, respectively. Compared to having a healthy BMI (n = 4 deaths; 0.2%), there was no association between being overweight (n = 12 deaths; 0.5%; OR: 2.33 (0.81, 8.36) or having obseity (n = 5 deaths; 0.6%; 2.52 (0.86, 9.12)) and age 51 mortality. There were no mortalities in the underweight group. When the regression was repeated in a maximal sample (n = 8011 with BMI and age 51 vital status data), associations were also null (overweight: 1.40 (0.64, 3.17); obesity: 1.39 (0.61, 3.21)).
Discussion
Findings suggest that the clinical obesity framework may provide a more meaningful classification than BMI alone. BMI does not provide clinical context [1, 2] and may misrepresent risk stratification for subsequent adverse outcomes. More than two-thirds of individuals with a BMI ≥ 30 kg/m² (‘obesity’) were categorised as having pre-clinical - rather than clinical -, obesity suggesting substantial heterogeneity within this BMI category. The modest correlation between BMI and clinical obesity definitions further underscores their conceptual and practical differences. Differences in demographic, behavioural, and health indicators were broadly similar across both frameworks, with more adverse profiles among individuals with clinical obesity or BMI-defined obesity. There was some evidence to suggest that pre-clinical and clinical obesity were associated with increased risk of death over a 5-year period, whereas BMI-defined categories were not. This highlights the potential value of clinical obesity classification, however replication in other cohorts with longer follow-up periods and detailed mortality outcome data is needed. Reliance on BMI alone may not identify physiological complications, including functional limitations or obesity-related organ dysfunction at population levels, that may contribute to elevated mortality risk.
This framework therefore has substantial implications for both research and stratification of clinical care. Specifically, reclassifying and risk-stratifying clinical phenotypes can have important public-health implications for primary, secondary and tertiary prevention avenues across the life course. Further optimisation of diagnostic and risk classification tools is therefore essential. Future research is also needed to validate the definition across settings, age, sex and ethnic groups, and evaluate its added value in predicting adverse health outcomes. Utilising this approach may be a meaningful and applicable way to move beyond sole reliance on BMI score for obesity treatment management pathways.
Strengths of this study include the large age-homogenous sample, detailed ascertainment of clinical obesity and exploration of obesity-mortality associations over a short period in midlife. Limitations include approximations of the criteria to operationalise the clinical obesity definition within the cohort study, higher levels of missing data for the clinical obesity definition, lack of information on cause and date of death, and the small number of deaths, resulting in low statistical power and wide confidence intervals. Clinical obesity prevalence may have been underestimated due to higher adiposity levels (as indicated by BMI levels) in those who did not undertake the body composition tests required to categorise clinical obesity status.
In epidemiological research, this framework may offer a new lens to investigate the predictors and consequences of obesity that extend beyond excess adiposity. For example, future studies could examine how early-life, behavioural, or socioeconomic factors influence both the timing and risk of clinical obesity, including transitions from none to pre-clinical to clinical, and to better understand how each of pre-clinical and clinical forms are associated with distinct long-term chronic disease risk. Using a large, age-homogenous, birth cohort, we demonstrate the feasibility and utility of applying this definition population-representative data. Future research is needed to validate the definition across settings, age, sex and ethnic groups, and to assess its added value in predicting adverse health outcomes before it can be implemented for individual clinical decision making.
Data availability
Data from the 1970 British Cohort Study are available to bona fide researchers at UK Data Service held and distributed by the UK Data Service. [https://beta.ukdataservice.ac.uk/datacatalogue/series/series?id=200001].
References
Humphreys S. The unethical use of BMI in contemporary general practice. Br J Gen Pract. 2010;60:696–7. https://doi.org/10.3399/bjgp10X515548.
Rubino F, Cummings DE, Eckel RH, Cohen RV, Wilding JPH, Brown WA, et al. Definition and diagnostic criteria of clinical obesity. Lancet Diabetes Endocrinol. 2025;13:221–62. https://doi.org/10.1016/S2213-8587(24)00316-4.
Stein MJ, Freisling H, Leitzmann MF. Clinical obesity and all-cause and cause-specific mortality in UK Biobank. JAMA Intern Med. 2025. https://doi.org/10.1001/jamainternmed.2025.4978
Leitzmann MF, Stein MJ, Baurecht H, Freisling H. Excess adiposity and cancer: evaluating a preclinical-clinical obesity framework for risk stratification. EClinicalMedicine. 2025;83:103247. https://doi.org/10.1016/j.eclinm.2025.103247.
Dicker D, Karpati T, Promislow S, Reges O. Implications of the European Association for the Study of Obesity’s new framework definition of obesity: prevalence and association with all-cause mortality. Ann Intern Med. 2025. https://doi.org/10.7326/ANNALS-24-02547
Sullivan A, Brown M, Hamer M, Ploubidis GB. Cohort profile update: the 1970 British Cohort Study (BCS70). Int J Epidemiol. 2023;52:e179–e186.
Centers for Disease Control and Prevention. Adult BMI categories. 2024. https://www.cdc.gov/bmi/adult-calculator/bmi-categories.html.
Bush K, Kivlahan DR, McDonell MB, Fihn SD, Bradley KA. The audit alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking. ambulatory care quality improvement project (ACQUIP). alcohol use disorders identification test. Arch Intern Med. 1998;158:1789–95. https://doi.org/10.1001/archinte.158.16.1789.
Hamer M, Stamatakis E, Chastin S, Pearson N, Brown M, Gilbert E, et al. Feasibility of measuring sedentary time using data from a thigh-worn accelerometer. Am J Epidemiol. 2020;189:963–71. https://doi.org/10.1093/aje/kwaa047.
Blodgett JM, Ahmadi MN, Atkin AJ, Chastin S, Chan HW, Suorsa K, et al. Device-measured physical activity and cardiometabolic health: the Prospective Physical Activity, Sitting, and Sleep (ProPASS) consortium. Eur Heart J. 2024;45:458–71. https://doi.org/10.1093/eurheartj/ehad717.
White C. Update on the harmonisation of disability data collection in UK surveys (Part 1). Health Stat Q. 2011;51:3–30. https://pubmed.ncbi.nlm.nih.gov/21894156/.
Sabia S, Dugravot A, Dartigues JF, Abell J, Elbaz A, Kivimäki M, et al. Physical activity, cognitive decline, and risk of dementia: 28 year follow-up of Whitehall II cohort study. BMJ. 2017;357:j2709 https://doi.org/10.1136/bmj.j2709.
Rutter M, Tizard J, Whitmore K. Education, health and behaviour. London: Longmans; 1970. [Google Scholar].
Tennant R, Hiller L, Fishwick R, Platt S, Joseph S, Weich S, et al. The Warwick-Edinburgh Mental Well-being Scale (WEMWBS): development and UK validation. Health Qual Life Outcomes. 2007;5:63 https://doi.org/10.1186/1477-7525-5-63.
van Burren S. Multiple imputation. In: Flexible Imputation of Missing Data. 2nd ed. New York: Chapman and Hall/CRC; 2018. pp. 29–62.
Brown M, Peters A. 1970 British Cohort Study: Responses and Deaths User Guide (Version 6). London: UCL Centre for Longitudinal Studies; 2023. https://doc.ukdataservice.ac.uk/doc/8006/mrdoc/pdf/bcs70_response_and_deaths_user_guide_v6.pdf.
Funding
Blodgett is supported by the British Heart Foundation (BHF; Grant No. SP/F/20/150002) and Cancer Research UK (Grant No. PRCPJT-Nov23/100005), Mitchell is supported by Cancer Research UK (Grant No. PRCPJT-Nov23/100005) and BHF (Grant No. RG/F/25/ 110168). Hamer receives support from BHF (Grant Nos. RG/F/ 25/110168 and RG/F/25/110168) and University College London Hospitals NIHR Biomedical Research Centre.
Author information
Authors and Affiliations
Institute of Sport Exercise and Health, Division of Surgery and Interventional Sciences, University College London, London, UK
Joanna M. Blodgett, John J. Mitchell & Mark Hamer
University College London Hospitals NIHR Biomedical Research Centre, London, UK
Joanna M. Blodgett, Janine Makaronidis & Mark Hamer
Centre for Obesity Research, Division of Medicine, University College London, London, UK
Janine Makaronidis
Department of Diabetes and Metabolism, Royal London Hospital, Barts Health NHS Trust, London, UK
Janine Makaronidis
Authors
- Joanna M. Blodgett
- John J. Mitchell
- Janine Makaronidis
- Mark Hamer
Contributions
JMB was responsible for conducting all analyses and writing the first draft of manuscript. JJM, JM and MH contributed to results interpretation, writing subsequent manuscript drafts and approving final submitted version.
Corresponding author
Correspondence to Joanna M. Blodgett.
Ethics declarations
Competing interests
JM reports salary and research funding from the NIHR BRC, institutional research funding from Novo Nordisk, unrelated to this work. JM has a voluntary role in the Association for the Study of Obesity (ASO).
Ethics approval and consent to participate
All participants provided written, informed consent. Ethical approval was obtained from the National Research Ethics Service (NRES) Committee South East Coast – Brighton and Sussex (Ref. 15/LO/1446). Further details are available from the study website and cohort profile (Sullivan et al., 2023; IJE). All methods were performed in accordance with the relevant guidelines and regulations.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Blodgett, J.M., Mitchell, J.J., Makaronidis, J. et al. Rethinking obesity: comparison of the new clinical obesity framework with traditional BMI-based classifications in midlife UK adults. Int J Obes (2026). https://doi.org/10.1038/s41366-026-02257-2
Received: 01 December 2025
Revised: 02 September 2026
Accepted: 19 October 2026
Published: 11 November 2026
Version of record: 11 November 2026
DOI: https://doi.org/10.1038/s41366-026-02257-2
来源:Nature 健康护理主题 · nature.com